Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis

Journal of Physiology

Volumn 593, Issue 8, 2015, Pages 1887-1899

  Sin, Thomas K ^a   Tam, Bjorn T ^a   Yung, Benjamin Y ^a   Yip, Shea P ^a   Chan, Lawrence W ^a   Wong, Cesar S ^a   Ying, Michael ^a   Rudd, John A ^b   Siu, Parco M ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DEUBIQUITINASE; DNA; DOXORUBICIN; E1A ASSOCIATED P300 PROTEIN; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; PROTEIN BAX; PROTEIN P53; PROTEIN USP7; RESVERATROL; SIRTUIN 1; SODIUM CHLORIDE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; ANTIOXIDANT; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE; USP7 PROTEIN, MOUSE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVITY; HEART PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN CONTENT; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; ANIMAL; CARDIAC MUSCLE CELL; DRUG EFFECTS; HEART; METABOLISM; OXIDATIVE STRESS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CARDIOTOXICITY; DOXORUBICIN; HEART; MICE; MYOCYTES, CARDIAC; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84927693531     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.270101     Document Type: Article

References (37)

1. Arafa MH, Mohammad NS, Atteia HH & Abd-Elaziz HR (2014). Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem 70, 701-711.
2. Aryal B, Jeong J & Rao VA (2014). Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicity. Proc Natl Acad Sci U S A 111, 2011-2016.
3. Bao GY, Wang HZ, Shang YJ, Fan HJ, Gu ML, Xia R, Qin Q & Deng AM (2012). Quantitative proteomic study identified cathepsin B associated with doxorubicin-induced damage in H9c2 cardiomyocytes. Biosci Trends 6, 283-287.
4. Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P, Khan M, Ovaa H, Terracciano CM, Barton PJ, Yacoub MH & Evans PC (2008). Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79, 472-480.
5. Danz ED, Skramsted J, Henry N, Bennett JA & Keller RS (2009). Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46, 1589-1597.
6. Dudka J, Gieroba R, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, Mandziuk S, Korobowicz E & Murias M (2012). Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med 2012, 606183.
7. Fang Z & Luna EJ (2013). Supervillin-mediated suppression of p53 protein enhances cell survival. J Biol Chem 288, 7918-7929.
8. Forman DE, Daniels KM, Cahalin LP, Zavin A, Allsup K, Cao P, Santhanam M, Joseph J, Arena R, Lazzari A, Schulze PC & Lecker SH (2014). Analysis of skeletal muscle gene expression patterns and the impact of functional capacity in patients with systolic heart failure. J Card Fail 20, 422-430.
9. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B & Sinclair DA (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196.
10. Jian B, Yang S, Chaudry IH & Raju R (2012). Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1. Mol Med 18, 209-214.
11. Kavazis AN, Smuder AJ & Powers SK (2014). Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle. J Appl Physiol (1985) 117, 223-230.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M & Stewart W (2006). Recommendations for chamber quantification. Eur J Echocardiogr 7, 79-108.
13. Lenneman AJ, Wang L, Wigger M, Frangoul H, Harrell FE, Silverstein C, Sawyer DB & Lenneman CG (2013). Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. Am J Cardiol 111, 609-612.
14. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J & Gu W (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653.
15. Liu J, Zheng H, Tang M, Ryu YC & Wang X (2008). A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol 295, H2541-H2550.
16. Lu TM, Tsai JY, Chen YC, Huang CY, Hsu HL, Weng CF, Shih CC & Hsu CP (2014). Downregulation of Sirt1 as aging change in advanced heart failure. J Biomed Sci 21, 57.
17. Moylan JS, Smith JD, Chambers MA, McLoughlin TJ & Reid MB (2008). TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am J Physiol Cell Physiol 295, C986-C993.
18. Oi N, Yuan J, Malakhova M, Luo K, Li Y, Ryu J, Zhang L, Bode AM, Xu Z, Lou Z & Dong Z (2014). Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene.
19. Oktem G, Uysal A, Oral O, Sezer ED, Olukman M, Erol A, Akgur SA & Bilir A (2012). Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp Toxicol Pathol 64, 471-479.
20. Osman AM, Al-Harthi SE, AlArabi OM, Elshal MF, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA & Osman OH (2013). Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals. Cancer Cell Int 13, 52.
21. Qureshi AA, Guan XQ, Reis JC, Papasian CJ, Jabre S, Morrison DC & Qureshi N (2012). Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor. Lipids Health Dis 11, 76.
22. Rezk YA, Balulad SS, Keller RS & Bennett JA (2006). Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194, e23-26.
23. Shalwala M, Zhu SG, Das A, Salloum FN, Xi L & Kukreja RC (2014). Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. PLoS One 9, e86977.
24. Sin TK, Yu AP, Yung BY, Yip SP, Chan LW, Wong CS, Ying M, Rudd JA & Siu PM (2014). Modulating effect of SIRT1 activation induced by resveratrol on Foxo1-associated apoptotic signalling in senescent heart. J Physiol 592, 2535-2548.
25. Sishi BJ, Bester DJ, Wergeland A, Loos B, Jonassen AK, van Rooyen J & Engelbrecht AM (2012). Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart. Exp Biol Med (Maywood) 237, 219-226.
26. Sishi BJ, Loos B, van Rooyen J & Engelbrecht AM (2013). Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity. Toxicology 309, 23-29.
27. Su S, Li Q, Liu Y, Xiong C, Li J, Zhang R, Niu Y, Zhao L, Wang Y & Guo H (2014). Sesamin ameliorates doxorubicin-induced cardiotoxicity: involvement of Sirt1 and Mn-SOD pathway. Toxicol Lett 224, 257-263.
28. Teng BT, Tam EW, Benzie IF & Siu PM (2011). Protective effect of caspase inhibition on compression-induced muscle damage. J Physiol 589, 3349-3369.
29. VonHoff DD, Rozencweig M, Layard M, Slavik M & Muggia FM (1977). Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 62, 200-208.
30. Wang S, Song P & Zou MH (2012). Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J Biol Chem 287, 8001-8012.
31. Weiss RB (1992). The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19, 670-686.
32. Wyke SM & Tisdale MJ (2006). Induction of protein degradation in skeletal muscle by a phorbol ester involves upregulation of the ubiquitin-proteasome proteolytic pathway. Life Sci 78, 2898-2910.
33. Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y & Azuma J (2008). Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79, 89-96.
34. Yang Y, Duan W, Lin Y, Yi W, Liang Z, Yan J, Wang N, Deng C, Zhang S, Li Y, Chen W, Yu S, Yi D & Jin Z (2013). SIRT1 activation by curcumin pretreatment attenuates mitochondrial oxidative damage induced by myocardial ischemia reperfusion injury. Free Radic Biol Med 65, 667-679.
35. Zhang C, Feng Y, Qu S, Wei X, Zhu H, Luo Q, Liu M, Chen G & Xiao X (2011). Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90, 538-545.
36. Zheng W, Lu YB, Liang ST, Zhang QJ, Xu J, She ZG, Zhang ZQ, Yang RF, Mao BB, Xu Z, Li L, Hao DL, Lu J, Wei YS, Chen HZ & Liu DP (2013). SIRT1 mediates the protective function of Nkx2.5 during stress in cardiomyocytes. Basic Res Cardiol 108, 364.
37. Zhu J, Zhang J, Xiang D, Zhang Z, Zhang L, Wu M, Zhu S, Zhang R & Han W (2010). Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol 643, 247-253.